Luye Pharma Group Ltd. (HKG:2186)

Market Cap	8.11B -50.0%
Revenue (ttm)	7.02B +4.1%
Net Income	688.55M +31.1%
EPS	0.18 +26.7%
Shares Out	3.99B
PE Ratio	11.49
Forward PE	9.97
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,492,000
Open	2.030
Previous Close	2.020
Day's Range	2.000 - 2.070
52-Week Range	1.730 - 4.490
Beta	0.87
Analysts	Buy
Price Target	3.53 (+73.89%)
Earnings Date	Aug 28, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by traum...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 5,221
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2186

Financial Performance

In 2025, Luye Pharma Group's revenue was 6.31 billion, an increase of 4.07% compared to the previous year's 6.06 billion. Earnings were 618.75 million, an increase of 31.12%.

Financial numbers in CNY

Analyst Summary

According to 2 analysts, the average rating for 2186 stock is "Buy." The 12-month stock price target is $3.53, which is an increase of 73.89% from the latest price.

Price Target

$3.53

(73.89% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 31, 2026

Data Sources Report a data error